Proteic binding partners of TCTP and methods of modulating tumor reversion or cell apoptosis
OwnerAdam Telerman, Robert Amson +3inventors
InventorsAdam Telerman, Robert Amson, Christophe Cans, Vanessa Nancy-Portebois, Brent Passer
Life of this patent
Estimating the term…
Abstract
This invention encompasses proteic binding partners of Translationally Controlled Tumor Protein (TCTP), which can modulate tumor reversion or cell apoptosis. Methods of screening for compounds useful for treating, preventing or managing cancer, an inflammatory disorder, or a neurodegenerative disorder and use of these compounds are also encompassed.
Claims24
A method of modulating tumor reversion or cell apoptosis comprising contacting a tumor cell with an effective amount of a proteic binding partner of TCTP.
A method of identifying a compound that alters binding between TCTP and a proteic binding partner of TCTP comprising:
- (a) contacting a candidate compound with TCTP and the proteic binding partner of TCTP;
- and
- (b) determining whether the binding between TCTP and the proteic binding partner of TCTP is altered as compared to the binding in the absence of the compound.
A method of identifying a compound useful for the treatment, prevention, and management of cancer comprising:
- (a) contacting a candidate compound with TCTP and a proteic binding partner of TCTP;
- (b) determining whether binding between TCTP and the proteic binding partner of TCTP is altered as compared to the binding in the absence of the compound;
- and wherein the binding between TCTP and the proteic binding partner is altered, then
- (c) contacting the compound with a tumor cell;
- and
- (d) determining whether tumor reversion or cell apoptosis is increased as compared to a tumor cell that has not been contacted with the compound;
- wherein tumor reversion of cell apoptosis is increased, the compound is useful for the treatment, prevention, or management of cancer.
A method of identifying a compound useful for the treatment, prevention, or management of a neurodegenerative disorder comprising:
- (a) contacting a candidate compound with TCTP and a proteic binding partner of TCTP;
- (b) determining whether binding between TCTP and the proteic binding partner of TCTP is altered as compared to the binding in the absence of the compound;
- and wherein the binding between TCTP and the proteic binding partner is altered, then
- (c) contacting the compound with a cell;
- and
- (d) determining whether cell apoptosis is reduced as compared to a cell that has not been contacted with the compound;
- wherein cell apoptosis is reduced, the compound is useful for the treatment, prevention, or management of a neurodegenerative disorder.
A method of identifying a compound useful for the treatment, prevention, or management of an inflammatory disorder comprising:
- (a) contacting a candidate compound with TCTP and a proteic binding partner of TCTP;
- (b) determining whether binding between TCTP and the proteic binding partner of TCTP is altered as compared to the binding in the absence of the compound;
- and wherein the binding between TCTP and the proteic binding partner is altered, then
- (c) determining whether the compound has an antiinflammatory activity;
- wherein the compound has an antiinflammatory activity, the compound is useful for the treatment, prevention, or management of an inflammatory disorder.
A method of determining the cause of cancer, an inflammatory disorder, or a neurodegenerative disorder in a patient suffering from said disorders comprising:
- (a) obtaining a first cell from the patient;
- (b) determining the binding between TCTP and a proteic binding partner in the first cell;
- (c) obtaining a second cell from a normal subject;
- (d) determining the binding between TCTP and the proteic binding partner in the second cell;
- and
- (e) comparing the bindings obtained from the first cell and the second cell and determining whether the binding in the first cell is altered;
- wherein the binding is altered, the cause of said disorders is attributed to said alteration of binding.
A method of diagnosing cancer or predicting the propensity for occurrence of cancer in a subject comprising:
- (a) obtaining a first cell from a potential patient;
- (b) determining the binding between TCTP and a proteic binding partner in the first cell;
- (c) obtaining a second cell from a normal subject;
- (d) determining the binding between TCTP and the proteic binding partner in the second cell;
- and
- (e) comparing the bindings obtained from the first cell and the second cell and determining whether the binding in the first cell is altered;
- wherein the binding is altered, the potential patient is diagnosed for cancer or has a higher than normal propensity for the occurrence of cancer.
Dependencies are inferred from the claim text.